Zhang Jingqi, Sui Yilun, Xiao Min, Sun Xiaoxi, Fu Jing
Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
J Assist Reprod Genet. 2025 Jan;42(1):165-183. doi: 10.1007/s10815-024-03319-y. Epub 2024 Nov 19.
The objective is to evaluate the effectiveness and safety of calcium ionophore as an artificial oocyte activation (AOA) method on pregnancy outcomes in different groups of intracytoplasmic sperm injection (ICSI) patients, providing potential evidence to establish consensus on the indications of AOA.
A systematic comprehensive search was performed in Medline, Embase, the Cochrane Library, and Google Scholar databases. Studies published from January 2014 to June 2024 were searched for analysis. All studies that compared ICSI with AOA-ICSI in routine indications composing impaired fertilization or embryo developmental arrest in previous cycles, or male-factor infertility were included.
Twelve studies were included in the meta-analysis. AOA-ICSI was associated with the increase in the overall fertilization rate (OR 1.99, 95% CI 1.16-3.41) and live birth rate (OR 4.58, 95% CI 1.52-13.80). All secondary outcomes including cleavage, blastocyst, high-quality embryo, implantation, biochemical pregnancy, clinical pregnancy presented superiority or equivalence in AOA-ICSI. And the use of calcium ionophore did not increase the miscarriage rate (OR 0.43, 95% CI 0.08-2.43). In subgroup analysis, AOA-ICSI exhibited a more significant effect on patients with indications of no or low fertilization. However, in patients with non-fertilization factors, no statistically significant improvements were observed in all outcomes.
Calcium ionophore is an effective artificial oocyte activation approach to improving pregnancy outcomes after ICSI, particularly in cases with indications of fertilization factors, providing further support for the application of AOA in specific populations. Further validation is needed to comprehensively establish the safety of AOA.
PROSPERO registration number CRD42024551481.
评估钙离子载体作为一种人工卵母细胞激活(AOA)方法对不同组别的卵胞浆内单精子注射(ICSI)患者妊娠结局的有效性和安全性,为就AOA的适应证达成共识提供潜在依据。
在Medline、Embase、Cochrane图书馆和谷歌学术数据库中进行系统全面的检索。检索2014年1月至2024年6月发表的研究进行分析。纳入所有在常规适应证(包括既往周期受精障碍或胚胎发育停滞,或男性因素不育)中比较ICSI与AOA-ICSI的研究。
荟萃分析纳入了12项研究。AOA-ICSI与总体受精率增加(OR 1.99,95%CI 1.16-3.41)和活产率增加(OR 4.58,95%CI 1.52-13.80)相关。所有次要结局,包括卵裂、囊胚、优质胚胎、着床、生化妊娠、临床妊娠,在AOA-ICSI中均表现出优势或等效性。并且使用钙离子载体未增加流产率(OR 0.43,95%CI 0.08-2.43)。在亚组分析中,AOA-ICSI对无受精或低受精指征的患者显示出更显著的效果。然而,在无受精因素的患者中,所有结局均未观察到统计学上的显著改善。
钙离子载体是一种有效的人工卵母细胞激活方法,可改善ICSI后的妊娠结局,尤其是在有受精因素指征的情况下,为AOA在特定人群中的应用提供了进一步支持。需要进一步验证以全面确定AOA的安全性。
PROSPERO注册号CRD42024551481。